[go: up one dir, main page]

CR20160072A - Compuestos y composiciones como inhibidores de la mek - Google Patents

Compuestos y composiciones como inhibidores de la mek

Info

Publication number
CR20160072A
CR20160072A CR20160072A CR20160072A CR20160072A CR 20160072 A CR20160072 A CR 20160072A CR 20160072 A CR20160072 A CR 20160072A CR 20160072 A CR20160072 A CR 20160072A CR 20160072 A CR20160072 A CR 20160072A
Authority
CR
Costa Rica
Prior art keywords
compounds
compositions
mek
inhibitors
cancer
Prior art date
Application number
CR20160072A
Other languages
English (en)
Inventor
Mark Gary Bock
Henrik Moebitz
Sunil Kumar Panigrahi
Ramulu Poddutoori
Susanta Samajdar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20160072A publication Critical patent/CR20160072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula I: en la cual n, R1, R2, R3a, R4 y R5 se definen en el Resumen de la Invención;capaz de inhibir la actividad de MEK. La invención proporciona además un procedimiento para la preparación de compuestos de la invención, las preparaciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos y composiciones en el manejo de enfermedadeshiperproliferativas similares al cáncer.
CR20160072A 2013-08-14 2016-02-12 Compuestos y composiciones como inhibidores de la mek CR20160072A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2418DE2013 2013-08-14
IN1686DE2014 2014-06-24
PCT/IB2014/063916 WO2015022662A1 (en) 2013-08-14 2014-08-14 Compounds and compositions as inhibitors of mek

Publications (1)

Publication Number Publication Date
CR20160072A true CR20160072A (es) 2016-05-09

Family

ID=51844790

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160072A CR20160072A (es) 2013-08-14 2016-02-12 Compuestos y composiciones como inhibidores de la mek

Country Status (33)

Country Link
US (3) US9227969B2 (es)
EP (1) EP3033343B1 (es)
JP (1) JP6473453B2 (es)
KR (1) KR102354208B1 (es)
CN (1) CN105473588B (es)
AP (1) AP2016008981A0 (es)
AU (1) AU2014307593C1 (es)
BR (1) BR112016001783B1 (es)
CA (1) CA2921300C (es)
CL (1) CL2016000150A1 (es)
CR (1) CR20160072A (es)
CU (1) CU20160020A7 (es)
DO (1) DOP2016000047A (es)
EA (1) EA029093B1 (es)
ES (1) ES2714718T3 (es)
GE (1) GEP201706725B (es)
HK (1) HK1219271A1 (es)
IL (1) IL243349A0 (es)
MX (1) MX359401B (es)
NI (1) NI201600014A (es)
PE (1) PE20160204A1 (es)
PH (1) PH12016500003A1 (es)
PL (1) PL3033343T3 (es)
PT (1) PT3033343T (es)
SG (1) SG11201510727VA (es)
SV (1) SV2016005153A (es)
TN (1) TN2015000574A1 (es)
TR (1) TR201902709T4 (es)
TW (1) TW201536782A (es)
UA (1) UA116566C2 (es)
UY (1) UY35704A (es)
WO (1) WO2015022662A1 (es)
ZA (1) ZA201509337B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
EP3250562B1 (en) 2015-01-30 2024-11-27 Biomed Valley Discoveries, Inc. Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
FI3307727T3 (fi) * 2015-06-15 2024-01-08 Asana Biosciences Llc Erk1:n ja erk2:n heterosyklisiä estäjiä ja niiden käyttö syövän hoidossa
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2019200216A1 (en) * 2018-04-12 2019-10-17 The Methodist Hospital System Modulation of irf-4 and uses thereof
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN110141657B (zh) * 2019-05-17 2023-01-17 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种表皮生长因子脂质体及其制备方法
JP2022547952A (ja) 2019-09-16 2022-11-16 ノバルティス アーゲー Ｂｒｄ９二機能性分解誘導薬及びその使用方法
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
AU2023238106A1 (en) * 2022-03-24 2024-09-26 Biomed Valley Discoveries, Inc. Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法
CN117800964A (zh) * 2022-09-30 2024-04-02 四川大学 PI3K/m-TOR抑制剂及其应用
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
ES2094141T3 (es) 1989-02-27 1997-01-16 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales.
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB8928281D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
AU2912997A (en) 1996-06-24 1998-01-14 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
CA2264908C (en) 1996-09-06 2006-04-25 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
WO2002016370A1 (en) 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2004161662A (ja) 2002-11-13 2004-06-10 Abbott Japan Co Ltd １ｈ−イミダゾキノリン誘導体
EP1590348A1 (en) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CN1747953A (zh) * 2002-12-20 2006-03-15 3M创新有限公司 芳基/杂芳基取代的咪唑并喹啉
EP1605943A4 (en) * 2003-03-07 2008-01-16 3M Innovative Properties Co 1-AMINO-1H-imidazoquinolines
JP4627298B2 (ja) 2003-07-02 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー チアゾール環で置換されたインドリル誘導体およびｐｐａｒ調整剤としてのその使用
BRPI0416801A (pt) * 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007035935A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
CA2634017A1 (en) 2005-12-16 2007-07-05 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
US9370508B2 (en) 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
MX336723B (es) 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
US8895581B2 (en) * 2010-05-17 2014-11-25 Boehringer Ingelheim International Gmbh 1H-imidazo[4,5-c]quinolines
BR112013001088A2 (pt) 2010-07-16 2016-05-24 Piramal Entpr Ltd "derivados substituídos como inibidores a quinase de imidazoquinolina"
AU2011301518B2 (en) 2010-09-16 2014-07-03 Hutchison Medipharma Limited Fused heteroaryls and their uses
BR112013013837A2 (pt) * 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP2854779A1 (en) 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek

Also Published As

Publication number Publication date
US20150051209A1 (en) 2015-02-19
CA2921300C (en) 2021-06-29
HK1219271A1 (zh) 2017-03-31
WO2015022662A1 (en) 2015-02-19
MX2016001980A (es) 2016-06-21
MX359401B (es) 2018-09-27
SG11201510727VA (en) 2016-02-26
CU20160020A7 (es) 2017-02-02
SV2016005153A (es) 2016-11-21
JP6473453B2 (ja) 2019-02-20
DOP2016000047A (es) 2016-08-31
EP3033343A1 (en) 2016-06-22
GEP201706725B (en) 2017-08-25
IL243349A0 (en) 2016-02-29
US10011599B2 (en) 2018-07-03
CL2016000150A1 (es) 2016-06-10
UA116566C2 (uk) 2018-04-10
US9227969B2 (en) 2016-01-05
PT3033343T (pt) 2019-03-21
EA029093B1 (ru) 2018-02-28
ZA201509337B (en) 2017-04-26
BR112016001783A2 (pt) 2017-08-01
PE20160204A1 (es) 2016-04-27
PH12016500003A1 (en) 2016-03-28
AU2014307593B2 (en) 2016-07-21
US9629836B2 (en) 2017-04-25
AU2014307593A1 (en) 2016-02-04
BR112016001783B1 (pt) 2022-07-05
US20160136150A1 (en) 2016-05-19
US20170183348A1 (en) 2017-06-29
ES2714718T3 (es) 2019-05-29
AP2016008981A0 (en) 2016-01-31
UY35704A (es) 2015-03-27
EP3033343B1 (en) 2018-12-05
CN105473588A (zh) 2016-04-06
TW201536782A (zh) 2015-10-01
KR102354208B1 (ko) 2022-01-20
JP2016530263A (ja) 2016-09-29
KR20160039203A (ko) 2016-04-08
NI201600014A (es) 2016-03-10
CN105473588B (zh) 2018-06-05
TN2015000574A1 (en) 2017-04-06
EA201690386A1 (ru) 2016-06-30
PL3033343T3 (pl) 2019-06-28
AU2014307593C1 (en) 2016-11-24
TR201902709T4 (tr) 2019-03-21
CA2921300A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
CR20150370A (es) Compuestos antivirales
UY35467A (es) Compuestos orgánicos
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
PE20171444A1 (es) Compuestos antivirales
MX2017013556A (es) Compuestos novedosos.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2015000076A (es) Benzamidas
UY35447A (es) Moduladores de p2x7
GT201500247A (es) Imidazopiridazinas sustituidas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201500931A1 (ru) Производные пиридин-4-ила
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.